Document:

Exhibit 4.1

 

FORM OF 

 

SECOND SUPPLEMENTAL INDENTURE 

 

between 

 

SACHEM CAPITAL CORP. 

 

and 

 

U.S. BANK NATIONAL ASSOCIATION

 

as Trustee 

 

Dated as of November 7, 2019

 

 

 

SECOND SUPPLEMENTAL INDENTURE 

 

THIS SECOND SUPPLEMENTAL INDENTURE (this
 “Second Supplemental Indenture”), dated as of November 7, 2019, is between Sachem Capital Corp., a New York corporation
(the “Company”), and U.S. Bank National Association, as trustee (the “Trustee”). Except as otherwise set
forth in this Second Supplemental Indenture, all capitalized terms used herein shall have the meaning set forth in the Base Indenture
(as defined below).

 

RECITALS OF THE COMPANY 

 

The Company and the Trustee executed and
delivered an Indenture, dated as of June 21, 2019 (the “Base Indenture” and, as supplemented by this Second Supplemental
Indenture, the “Indenture”), to provide for the issuance by the Company from time to time of the Company’s unsecured
debentures, notes or other evidences of indebtedness (the “Securities”), to be issued in one or more series as provided
in the Indenture.

 

The Company desires to issue and sell up
to $30,000,000 aggregate principal amount (or up to $34,500,000 aggregate principal amount if the underwriters’ option to
purchase additional Securities is exercised in full) of the Company’s 6.875% Notes due December 30, 2024 (the “Notes”).

 

Sections 901(4) and 901(6) of the Base Indenture
provide that without the consent of Holders of the Securities of any series issued under the Indenture, the Company, when authorized
by or pursuant to a Board Resolution, and the Trustee, at any time and from time to time, may enter into one or more indentures
supplemental to the Base Indenture to (i) change or eliminate any of the provisions of the Base Indenture when there is no
Security Outstanding of any series created prior to the execution of the supplemental indenture that is entitled to the benefit
of such provision and (ii) establish the form or terms of Securities of any series as permitted by Section 201 and Section 301
of the Base Indenture.

 

     

     

    

 

The Company desires to establish the form
and terms of the Notes and to modify, alter, supplement and change certain provisions of the Base Indenture for the benefit of
the Holders of the Notes (except as may be provided in a future supplemental indenture to the Base Indenture (“Future Supplemental
Indenture”).

 

The Company has duly authorized the execution
and delivery of this Second Supplemental Indenture to provide for the issuance of the Notes and all acts and things necessary to
make this Second Supplemental Indenture a valid, binding, and legal obligation of the Company and to constitute a valid agreement
of the Company, in accordance with its terms, have been done and performed.

 

NOW, THEREFORE, for and in consideration
of the premises and the purchase of the Notes by the Holders thereof, it is mutually agreed, for the equal and proportionate benefit
of all Holders of the Notes, as follows:

 

ARTICLE I.

 

TERMS OF THE NOTES

 

Section 1.01. 
Terms of the Notes. The following terms relating to the Notes are hereby established:

 

(a)  
The Notes shall constitute a series of Senior Securities having the title “6.875% Notes due December 30, 2024.”
The Notes shall bear a CUSIP number of 78590A 307 and an ISIN of US78590A3077.

 

(b)  
The aggregate principal amount of the Notes that may be initially authenticated and delivered under the Indenture (except
for Notes authenticated and delivered upon registration of, transfer of, or in exchange for, or in lieu of, other Notes pursuant
to Sections 304, 305, 306, 906, 1107 or 1305 of the Base Indenture, and except for any Securities that, pursuant to Section 303
of the Base Indenture, are deemed never to have been authenticated and delivered under the Indenture) shall be up to $30,000,000
(or up to $34,500,000 aggregate principal amount if the underwriters’ option to purchase additional Securities is exercised
in full). Under a Board Resolution, Officers’ Certificate pursuant to Board Resolutions or an indenture supplement, the Company
may from time to time, without the consent of the Holders of Notes, issue additional Notes (in any such case “Additional
Notes”) having the same ranking and the same interest rate, maturity and other terms as the Notes. Any Additional Notes and
the existing Notes will constitute a single series under the Indenture and all references to the relevant Notes herein shall include
the Additional Notes unless the context otherwise requires.

 

(c)  
The entire outstanding principal of the Notes shall be payable on December 30, 2024, unless earlier redeemed or repurchased
in accordance with the provisions of the Indenture.

 

    2

     

    

 

(d)  
The rate at which the Notes shall bear interest shall be 6.875% per annum. The Interest Payment Dates for the Notes shall
be March 30, June 30, September 30 and December 30 of each year, commencing December 30, 2019 (if an Interest Payment Date
falls on a day that is not a Business Day, then the applicable interest payment will be made on the next succeeding Business Day
and no additional interest will accrue as a result of such delayed payment). The initial interest period will be the period from
and including November 7, 2019, to, but excluding, December 30, 2019, and the subsequent interest periods will be the periods from
and including an Interest Payment Date to, but excluding, the next Interest Payment Date or the Stated Maturity, as the case may
be; the interest so payable, and punctually paid or duly provided for, on any Interest Payment Date, will be paid to the Person
in whose name the Note (or one or more Predecessor Securities) is registered at the close of business on the Regular Record Date
for such interest, which shall be March 15, June 15, September 15, or December 15 (whether or not a Business Day), as the case
may be, immediately preceding such Interest Payment Date. Payment of principal of (and premium, if any, on) and any such interest
on the Notes will be made at the office of the Trustee located at 111 Fillmore Avenue, St. Paul, MN 55107, Attention: Sachem Capital
Corp. (6.875% Notes Due December 30, 2024) (Karen R. Beard, Vice President) or at such other address as designated by the Trustee,
in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public and private
debts; provided, however, that at the option of the Company payment of interest may be made by check mailed to the address
of the Person entitled thereto as such address shall appear in the Security Register; provided, further, however, that so
long as the Notes are registered to Cede & Co., such payment will be made by wire transfer in accordance with the procedures
established by The Depository Trust Company and the Trustee. Interest on the Notes will be computed on the basis of a 360-day year
of twelve 30-day months.

 

(e)  
The Notes shall be initially issuable in global form (each such Note, a “Global Note”). The Global Notes and
the Trustee’s certificate of authentication thereon shall be substantially in the form of Exhibit A to this Second
Supplemental Indenture. Each Global Note shall represent the outstanding Notes as shall be specified therein and each shall provide
that it shall represent the aggregate amount of outstanding Notes from time to time endorsed thereon and that the aggregate amount
of outstanding Notes represented thereby may from time to time be reduced or increased, as appropriate, to reflect exchanges and
redemptions. Any endorsement of a Global Note to reflect the amount of any increase or decrease in the amount of outstanding Notes
represented thereby shall be made by the Trustee or the Security Registrar, in accordance with Sections 203 and 305 of the Base
Indenture.

 

(f)   
The depositary for such Global Notes (the “Depositary”) shall be The Depository Trust Company, New York, New
York. The Security Registrar with respect to the Global Notes shall be the Trustee.

 

(g)  
The Notes shall be defeasible pursuant to Section 1402 or Section 1403 of the Base Indenture. Covenant defeasance
contained in Section 1403 of the Base Indenture shall apply to the covenants contained in Sections 1006, 1008 and 1009 of
the Indenture.

 

(h)  
The Notes shall be redeemable pursuant to Section 1101 of the Base Indenture and as follows:

 

(i)          
The Notes will be redeemable in whole or in part at any time or from time to time, at the option of the Company, on or after
November 7, 2021, at a redemption price equal to 100% of the outstanding principal amount thereof, plus accrued and unpaid interest
payments otherwise payable for the then-current quarterly interest period accrued to, but excluding, the date fixed for redemption.

 

    3

     

    

 

(ii)       
Notice of redemption shall be given in writing and mailed, first-class postage prepaid or by overnight courier guaranteeing
next-day delivery, to each Holder of the Notes to be redeemed, not less than thirty (30) nor more than sixty (60) days
prior to the Redemption Date, at the Holder’s address appearing in the Security Register. All notices of redemption shall
contain the information set forth in Section 1104 of the Base Indenture.

 

(iii)     
If the Company elects to redeem only a portion of the Notes, the Trustee will determine the method for selecting the particular
Notes to be redeemed, in accordance with Section 1103 of the Base Indenture and the Investment Company Act and the rules of
any national securities exchange or quotation system on which the Notes are listed, in each case to the extent applicable.

 

(iv)      
Unless the Company defaults in payment of the Redemption Price, on and after the Redemption Date, interest will cease to
accrue on the Notes called for redemption.

 

(i)    
The Notes shall not be subject to any sinking fund pursuant to Section 1201 of the Base Indenture.

 

(j)    
The Notes shall be issuable in denominations of $25 and integral multiples of $25 in excess thereof.

 

(k)  
Holders of the Notes will not have the option to have the Notes repaid prior to the Stated Maturity.

 

(l)    
The Notes are hereby designated as “Senior Securities” under the Indenture.

 

ARTICLE II.

 

COVENANTS

 

Section 2.01. 
Except as may be provided in a Future Supplemental Indenture, for the benefit of the Holders of the Notes but no other
series of Securities under the Indenture, whether now or hereafter issued and Outstanding, Article Ten of the Base Indenture shall
be amended by adding the following new Sections 1009, and 1010 thereto, each as set forth below:

 

“Section 1009. Asset Coverage Ratio.

 

The Company hereby agrees that for the period
of time during which Notes are Outstanding, the Company will not pay any dividends or make any distributions in excess of 90% of
its taxable income, incur any Indebtedness or purchase any shares of its outstanding capital stock, unless, in every such case,
at the time of the incurrence of such Indebtedness or at the time of any such dividend, distribution or purchase, the Company has
an Asset Coverage of at least 150% after giving effect to the incurrence of such Indebtedness and the application of the net proceeds
therefrom or after deducting the amount of such purchase, price as the case may be. “Asset Coverage” means the ratio
(expressed as a percentage) which the total assets of the Company bears to the aggregate amount of indebtedness (including the
aggregate principal amount of the involuntary liquidation preference of redeemable preferred stock, if any), of the Company. For
purposes of the Supplemental Indenture, “Indebtedness” means, without duplication: (a) all indebtedness for borrowed
money; (b) all obligations evidenced by notes, bonds, debentures or similar instruments; and (c) any lease of, or other arrangement
conveying the right to use, any property by a Person as lessee that has been or should be accounted for as a capital lease on a
balance sheet of such Person prepared in accordance with GAAP.

 

    4

     

    

 

“Section 1010. Commission Reports and Reports
to Holders.

 

If, at any time, the Company is not subject
to the reporting requirements of Sections 13 or 15(d) of the Exchange Act to file any periodic reports with the Commission, the
Company agrees to furnish to the Holders of Notes and the Trustee for the period of time during which the Notes are Outstanding:
(i) within 90 days after the end of the each fiscal year of the Company (which fiscal year ends on December 31), audited annual
consolidated financial statements of the Company and (ii) within 45 days after the end of each fiscal quarter of the Company
(other than the Company’s fourth fiscal quarter), unaudited interim consolidated financial statements of the Company. All
such financial statements shall be prepared, in all material respects, in accordance with GAAP.”

 

ARTICLE III.

 

MEETINGS OF HOLDERS OF SECURITIES

 

Section 3.01. 
Except as may be provided in a Future Supplemental Indenture, for the benefit of the Holders of the Notes but no other
series of Securities under the Indenture, whether now or hereafter issued and Outstanding, Section 1505 of the Base Indenture
shall be amended by replacing clause (c) thereof with the following:

 

“(c) At any meeting of Holders, each
Holder of a Security of such series or proxy shall be entitled to one vote for each $25.00 principal amount of the Outstanding
Securities of such series held or represented by such Holder; provided, however, that no vote shall be cast or counted
at any meeting in respect of any Security challenged as not Outstanding and ruled by the chairman of the meeting to be not Outstanding.
The chairman of the meeting shall have no right to vote, except as a Holder of a Security of such series or proxy.”

 

ARTICLE IV.

 

MISCELLANEOUS

 

Section 4.01. 
This Second Supplemental Indenture and the Notes shall be governed by and construed in accordance with the law of the
State of New York, without regard to principles of conflicts of laws. This Second Supplemental Indenture is subject to the provisions
of the Trust Indenture Act that are required to be part of the Indenture and shall, to the extent applicable, be governed by such
provisions.

 

    5

     

    

 

Section 4.02. 
In case any provision in this Second Supplemental Indenture or in the Notes shall be invalid, illegal or unenforceable,
the validity, legality and enforceability of the remaining provisions shall not in any way be affected or impaired thereby.

 

Section 4.03. 
This Second Supplemental Indenture may be executed in counterparts, each of which will be an original, but such counterparts
will together constitute but one and the same Second Supplemental Indenture. The exchange of copies of this Second Supplemental
Indenture and of signature pages by facsimile, .pdf transmission, email or other electronic means shall constitute effective execution
and delivery of this Second Supplemental Indenture for all purposes. Signatures of the parties hereto transmitted by facsimile,
..pdf transmission, email or other electronic means shall be deemed to be their original signatures for all purposes.

 

Section 4.04. 
The Base Indenture, as supplemented and amended by this Second Supplemental Indenture, is in all respects ratified and
confirmed, and the Base Indenture and this Second Supplemental Indenture shall be read, taken and construed as one and the same
instrument with respect to the Notes. All provisions included in this Second Supplemental Indenture supersede any conflicting provisions
included in the Base Indenture with respect to the Notes, unless not permitted by law. The Trustee accepts the trusts created by
the Base Indenture, as supplemented by this Second Supplemental Indenture, and agrees to perform the same upon the terms and conditions
of the Base Indenture, as supplemented by this Second Supplemental Indenture.

 

Section 4.05. 
The provisions of this Second Supplemental Indenture shall become effective as of the date hereof.

 

Section 4.06. 
Notwithstanding anything else to the contrary herein, the terms and provisions of this Second Supplemental Indenture
shall apply only to the Notes and shall not apply to any other series of Securities under the Base Indenture and this Second Supplemental
Indenture shall not and does not otherwise affect, modify, alter, supplement or change the terms and provisions of any other series
of Securities under the Base Indenture, whether now or hereafter issued and Outstanding.

 

Section 4.07. 
The recitals contained herein and in the Notes shall be taken as the statements of the Company, and the Trustee assumes
no responsibility for their correctness. The Trustee makes no representations as to the validity or sufficiency of this Second
Supplemental Indenture, the Notes or any Additional Notes, except that the Trustee represents that it is duly authorized to execute
and deliver this Second Supplemental Indenture, authenticate the Notes and any Additional Notes and perform its obligations hereunder.
The Trustee shall not be accountable for the use or application by the Company of the Notes or any Additional Notes or the proceeds
thereof.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT
BLANK]

 

    6

     

    

 

IN WITNESS WHEREOF, the parties hereto have
caused this Second Supplemental Indenture to be duly executed as of the date first above written.

 

	 	SACHEM CAPITAL CORP.
	 	 	 
	 	By:	 
	 	Name:	John L. Villano
	 	Title:	Co-Chief Executive Officer
	 	 	 
	 	U.S. BANK NATIONAL
 ASSOCIATION, as Trustee

	 	 
	 	By:	 
	 	Name:	 
	 	Title:	 

 

[Signature page to Second Supplemental
Indenture]

 

    

     

    

 

Exhibit A – Form of Global Note

 

This Security is a Global Security within
the meaning of the Indenture hereinafter referred to and is registered in the name of The Depository Trust Company or a nominee
thereof. This Security may not be exchanged in whole or in part for a Security registered, and no transfer of this Security in
whole or in part may be registered, in the name of any Person other than The Depository Trust Company or a nominee thereof, except
in the limited circumstances described in the Indenture.

 

Unless this certificate is presented
by an authorized representative of The Depository Trust Company to the issuer or its agent for registration of transfer, exchange
or payment and such certificate issued in exchange for this certificate is registered in the name of Cede & Co., or such
other name as requested by an authorized representative of The Depository Trust Company, any transfer, pledge or other use hereof
for value or otherwise by or to any person is wrongful, as the registered owner hereof, Cede & Co., has an interest herein.

 

Sachem Capital Corp. 

 

	No.	
        $                    

        CUSIP No.: 78590A 307

        ISIN:  US78590A3077

         

 

6.875% Notes due December 30, 2024

 

Sachem Capital Corp., a corporation duly
organized and existing under the laws of New York (herein called the “Company”, which term includes any successor Person
under the Indenture hereinafter referred to), for value received, hereby promises to pay to Cede & Co., or registered
assigns, the principal sum of THIRTY MILLION AND 00/100 Dollars (U.S. $30,000,000.00) on December 30, 2024 and to pay interest
thereon from November 7, 2019 or from the most recent Interest Payment Date to which interest has been paid or duly provided for,
quarterly on March 30, June 30, September 30 and December 30 in each year, commencing December 30, 2019, at the rate of 6.875%
per annum, until the principal hereof is paid or made available for payment. The interest so payable, and punctually paid or duly
provided for, on any Interest Payment Date will, as provided in such Indenture, be paid to the Person in whose name this Security
is registered at the close of business on the Regular Record Date for such interest, which shall be March 15, June 15,
September 15, or December 15 (whether or not a Business Day), as the case may be, immediately preceding such Interest
Payment Date. Any such interest not so punctually paid or duly provided for will forthwith cease to be payable to the Holder on
such Regular Record Date and may either be paid to the Person in whose name this Security is registered at the close of business
on a Special Record Date for the payment of such Defaulted Interest to be fixed by the Trustee, notice whereof shall be given to
Holders of Securities of this series not less than 10 days prior to such Special Record Date, or be paid at any time in any other
lawful manner not inconsistent with the requirements of any securities exchange on which the Securities of this series may be listed,
and upon such notice as may be required by such exchange, all as more fully provided in said Indenture. This Security may be issued
as part of a series.

 

    

     

    

 

Payment of the principal of (and premium,
if any, on) and any such interest on this Security will be made at the office of the Trustee located at 111 Fillmore Avenue, St.
Paul, MN55107, Attention: Sachem Capital Corp. (6.875% Notes Due December 30, 2024) or at such other address as designated by the
Trustee, in such coin or currency of the United States of America as at the time of payment is legal tender for payment of public
and private debts; provided, however, that at the option of the Company payment of interest may be made by check
mailed to the address of the Person entitled thereto as such address shall appear in the Security Register; provided, further,
however, that so long as this Security is registered to Cede & Co., such payment will be made by wire transfer in
accordance with the procedures established by The Depository Trust Company and the Trustee.

 

Reference is hereby made to the further
provisions of this Security set forth on the reverse hereof, which further provisions shall for all purposes have the same effect
as if set forth at this place.

 

Unless the certificate of authentication
hereon has been executed by the Trustee referred to on the reverse hereof by manual signature, this Security shall not be entitled
to any benefit under the Indenture or be valid or obligatory for any purpose.

 

    

     

    

 

IN WITNESS WHEREOF, the Company has caused
this instrument to be duly executed.

Dated:

 

	 	SACHEM CAPITAL CORP.
	 	 	 
	 	By:	 
	 	Name:
	 	Title:

 

	 	 
	Attest	 
	 	 
	By:	 	 	 
	 	Name:	 
	 	Title:	 

 

[Global Note - Second Supplemental Indenture]

 

    

     

    

 

CERTIFICATE OF AUTHENTICATION

 

This is one of the Securities of the series
designated therein referred to in the within-mentioned Indenture.

 

Dated:

 

	 	U.S. BANK NATIONAL ASSOCIATION, as Trustee
	 	 	 
	 	By:	 
	 	Authorized Signatory

 

[Global Note - Second Supplemental Indenture]

 

    

     

    

 

Sachem Capital Corp. 

 

6.875% Notes due December 30, 2024

 

This Security is one of a duly authorized
issue of Senior Securities of the Company (herein called the “Securities”), issued and to be issued in one or more
series under an Indenture, dated as of June 21, 2019 (herein called the “Base Indenture”, which term shall have the
meaning assigned to it in such instrument), between the Company and U.S. Bank National Association, as Trustee (herein called the
 “Trustee”, which term includes any successor trustee under the Base Indenture), and reference is hereby made to the
Base Indenture for a statement of the respective rights, limitations of rights, duties and immunities thereunder of the Company,
the Trustee, and the Holders of the Securities and of the terms upon which the Securities are, and are to be, authenticated and
delivered, as supplemented by the Second Supplemental Indenture, dated as of November 7, 2019, by and between the Company and the
Trustee (herein called the “Second Supplemental Indenture”; the Second Supplemental Indenture and the Base Indenture
collectively are herein called the “Indenture”). In the event of any conflict between the Base Indenture and the Second
Supplemental Indenture, the Second Supplemental Indenture shall govern and control.

 

This Security is one of the series designated
on the face hereof, which series is initially limited in aggregate principal amount to $30,000,000.00. Under a Board Resolution,
Officers’ Certificate pursuant to Board Resolutions or an indenture supplement, the Company may from time to time, without
the consent of the Holders of Securities, issue additional Securities of this series (in any such case “Additional Securities”)
having the same ranking and the same interest rate, maturity and other terms as the Securities. Any Additional Securities and the
existing Securities will constitute a single series under the Indenture and all references to the relevant Securities herein shall
include the Additional Securities unless the context otherwise requires. The aggregate amount of outstanding Securities represented
hereby may from time to time be reduced or increased, as appropriate, to reflect exchanges and redemptions.

 

The Securities of this series are subject
to redemption in whole or in part at any time or from time to time, at the option of the Company, on or after November 7, 2021,
at a redemption price per security equal to 100% of the outstanding principal amount thereof plus accrued and unpaid interest payments
otherwise payable for the then-current quarterly interest period accrued to, but excluding, the date fixed for redemption.

 

Notice of redemption shall be given in writing
and mailed, first-class postage prepaid or by overnight courier guaranteeing next-day delivery, to each Holder of the Securities
to be redeemed, not less than thirty (30) nor more than sixty (60) days prior to the Redemption Date, at the Holder’s
address appearing in the Security Register. All notices of redemption shall contain the information set forth in Section 1104
of the Base Indenture.

 

If the Company elects to redeem only a portion
of the Securities, the Trustee will determine the method for selecting the particular Securities to be redeemed, in accordance
with Section 1.01 of the Second Supplemental Indenture and Section 1103 of the Base Indenture. In the event of redemption
of this Security in part only, a new Security or Securities of this series and of like tenor for the unredeemed portion hereof
will be issued in the name of the Holder hereof upon the cancellation hereof.

 

    

     

    

 

Unless the Company defaults in payment of
the Redemption Price, on and after the Redemption Date, interest will cease to accrue on the Securities called for redemption.

 

Holders of Securities do not have the option
to have the Securities repaid prior to December 30, 2024.

 

The Indenture contains provisions for defeasance
at any time of the entire indebtedness of this Security or certain restrictive covenants and Events of Default with respect to
this Security, in each case upon compliance with certain conditions set forth in the Indenture.

 

If an Event of Default with respect to Securities
of this series shall occur and be continuing, the principal of the Securities of this series may be declared due and payable in
the manner and with the effect provided in the Indenture.

 

The Indenture permits, with certain exceptions
as therein provided, the amendment thereof and the modification of the rights and obligations of the Company and the rights of
the Holders of the Securities of each series to be affected under the Indenture at any time by the Company and the Trustee with
the consent of the Holders of not less than a majority in principal amount of the Securities at the time Outstanding of each series
to be affected. The Indenture also contains provisions permitting the Holders of specified percentages in principal amount of the
Securities of each series at the time Outstanding, on behalf of the Holders of all Securities of such series, to waive compliance
by the Company with certain provisions of the Indenture and certain past defaults under the Indenture and their consequences. Any
such consent or waiver by the Holder of this Security shall be conclusive and binding upon such Holder and upon all future Holders
of this Security and of any Security issued upon the registration of transfer hereof or in exchange herefor or in lieu hereof,
whether or not notation of such consent or waiver is made upon this Security.

 

As provided in and subject to the provisions
of the Indenture, the Holder of this Security shall not have the right to institute any proceeding with respect to the Indenture
or for the appointment of a receiver or trustee or for any other remedy thereunder, unless such Holder shall have previously given
the Trustee written notice of a continuing Event of Default with respect to the Securities of this series, the Holders of not less
than 25% in principal amount of the Securities of this series at the time Outstanding shall have made written request to the Trustee
to institute proceedings in respect of such Event of Default as Trustee and offered the Trustee indemnity, security, or both satisfactory
to the Trustee against the costs, expenses and liabilities to be incurred in compliance with such request, and the Trustee shall
not have received from the Holders of a majority in principal amount of Securities of this series at the time Outstanding a direction
inconsistent with such request, and shall have failed to institute any such proceeding, for sixty (60) days after receipt
of such notice, request and offer of indemnity and/or security. The foregoing shall not apply to any suit instituted by the Holder
of this Security for the enforcement of any payment of principal hereof or any premium or interest hereon on or after the respective
due dates expressed herein.

 

    

     

    

 

No reference herein to the Indenture and
no provision of this Security or of the Indenture shall alter or impair the obligation of the Company, which is absolute and unconditional,
to pay the principal of and any premium and interest on this Security at the times, place and rate, and in the coin or currency,
herein prescribed.

 

As provided in the Indenture and subject
to certain limitations therein set forth, the transfer of this Security is registrable in the Security Register, upon surrender
of this Security for registration of transfer at the office or agency of the Company in any place where the principal of and any
premium and interest on this Security are payable, duly endorsed by, or accompanied by a written instrument of transfer in form
satisfactory to the Company and the Security Registrar duly executed by, the Holder hereof or his attorney duly authorized in writing,
and thereupon one or more new Securities of this series and of like tenor, of authorized denominations and for the same aggregate
principal amount, will be issued to the designated transferee or transferees.

 

The Securities of this series are issuable
only in registered form without coupons in denominations of $25 and any integral multiples of $25 in excess thereof. As provided
in the Indenture and subject to certain limitations therein set forth, Securities of this series are exchangeable for a like aggregate
principal amount of Securities of this series and of like tenor of a different authorized denomination, as requested by the Holder
surrendering the same.

 

No service charge shall be made for any
such registration of transfer or exchange, but the Company, the Trustee, or the Security Registrar may require payment of a sum
sufficient to cover any tax or other governmental charge payable in connection therewith.

 

Prior to due presentment of this Security
for registration of transfer, the Company, the Trustee, or the Security Registrar and any agent of the Company, the Trustee, or
the Security Registrar may treat the Person in whose name this Security is registered as the owner hereof for all purposes, whether
or not this Security be overdue, and none of the Company, the Trustee, the Security Registrar or any agent thereof shall be affected
by notice to the contrary.

 

All terms used in this Security which are
defined in the Indenture shall have the meanings assigned to them in the Indenture.

 

The Indenture and this Security shall be
governed by and construed in accordance with the laws of the State of New York, without regard to principles of conflicts of laws.

 

To the extent any provision of this Security
conflicts with the express provisions of the Indenture, the provisions of the Indenture shall govern and be controlling.Exhibit

Exhibit 10.1

GENMARK DIAGNOSTICS, INC
EXECUTIVE SEVERANCE PLAN

1. ESTABLISHMENT AND PURPOSE OF PLAN
1.1    Establishment.  The GenMark Diagnostics, Inc. Executive Severance Plan (the “Plan”) is hereby established by the Compensation Committee (the “Committee”) of the Board of Directors of GenMark Diagnostics, Inc., effective July 31, 2019 (the “Effective Date”).
1.2    Purpose.  The Company draws upon the knowledge, experience and advice of its senior leadership team in order to manage its business for the benefit of the Company’s stockholders.  The Committee has determined that it is in the best interests of the Company and its stockholders to provide for the continued dedication of its employees by establishing this Plan to provide severance benefits to eligible employees whose employment terminates under circumstances described in this Plan.
2.     DEFINITIONS AND CONSTRUCTION
2.1    Definitions.  Whenever used in this Plan, the following terms shall have the meanings set forth below:
(a)“Accrued Amounts” mean, collectively:
(1)any accrued but unpaid base salary prorated to the Termination Date and accrued but unused vacation, both of which shall be paid on the Termination Date in accordance with the Company’s customary payroll procedures;
(2)reimbursement of unreimbursed business expenses properly incurred by the Participant, which shall be subject to, and paid in accordance with, the Company’s expense reimbursement policy; and
(3)such employee benefits (including equity compensation), if any, to which the Participant may be entitled under the Company’s employee benefit plans as of the Termination Date.
(b)“Acquiror” means the surviving, continuing, successor, or purchasing corporation or other business entity or parent thereof, as the case may be, in connection with a Change in Control.
(c)“Base Salary Rate” means the Participant’s monthly base salary rate in effect immediately prior to the Participant’s termination of employment (without giving effect to any reduction in the Participant’s base salary rate constituting Good Reason).  Base Salary Rate does not include any bonuses, commissions, fringe benefits, car allowances, other irregular payments or any other compensation except base salary.
(d)“Board” means the Board of Directors of the Company.
(e)“Cause” means the occurrence of any of the following:
(1)the Participant’s theft, dishonesty, willful misconduct, breach of fiduciary duty for personal profit, or falsification of any Company documents or records; or
(2)the Participant’s unauthorized use, misappropriation, destruction or diversion of any tangible or intangible asset or corporate opportunity of the Company (including, without limitation, the Participant’s improper use or disclosure of the Company’s confidential or proprietary information); or
(3)the Participant’s substantial and continuing willful refusal to perform duties ordinarily performed by an employee in the same or similar position; or

(4)the Participant’s conviction (including any plea of guilty or nolo contendere) of a felony, or of a misdemeanor which would have a material adverse effect on the Company’s goodwill if the Participant were to be retained as an employee of the Company; or
(5)the Participant’s willful failure to comply with the written policies and procedures of the Company including but not limited to the Company’s Code of Business Conduct and the Company’s Insider Trading Policy.
(f)“Change in Control” means the occurrence of any of the following after the Effective Date:
(1)Any one person, or more than one person acting as a group (a “Person”) acquires ownership of the Company’s securities that, together with the stock held by such Person, constitutes more than fifty percent (50%) of the total voting power of the Company’s then outstanding stock.  The term “Person” shall include any natural person, corporation, partnership, trust, or association, or any group or combination thereof, whose ownership of the Company’s securities would be required to be reported under Regulation 13(D) under the Securities Exchange Act of 1934, as amended, or any similar successor regulation or rule.  For purposes of this clause (1), if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change in Control;
(2)A change in the effective control of the Company which occurs on the date that a majority of the members of the Board is replaced during any twelve (12) month period by members of the Board whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election; or
(3)The closing of any transaction involving a change in ownership of a substantial portion of the Company’s assets, which occurs on the date that any Person acquires (or has acquired during any twelve (12) month period ending on the date of the most recent acquisition by such Person or Persons) assets from the Company that have a total gross fair market value equal to or more than fifty percent (50%) of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions.  For purposes of this clause (3), gross fair market value means the value of the assets of the Company, or the value of the assets being disposed of, determined without regard to any liabilities associated with such assets.
Notwithstanding the foregoing, the term “Change in Control” shall not include a consolidation, merger, or other reorganization if, upon consummation of such transaction, all of the outstanding voting stock of the Company is owned, directly or indirectly, by a holding company, and the holders of the Company’s common stock immediately prior to the transaction have substantially the same proportionate ownership and voting control of such holding company immediately after such transaction.
(g)“Change in Control Period” means the period beginning on the date ninety (90) days preceding the date of an event constituting a Change in Control and ending with the close of business on the first anniversary of the date of such event.
(h)“CIC Severance Benefit Period” means, for each Participant, the CIC Severance Benefit Period set forth in the Participant’s Participation Agreement, which will apply in connection with a Qualifying Termination that occurs during a Change in Control Period.
(i)“Code” means the Internal Revenue Code of 1986, as amended, or any successor thereto and any applicable regulations promulgated thereunder.
(j)“Committee” means the Compensation Committee of the Board.
(k)“Company” means GenMark Diagnostics, Inc., a Delaware corporation, and a Successor that agrees to assume all of the rights and obligations of the Company under this Plan or a Successor which otherwise becomes bound by operation of law under this Plan.
(l)“Company Group” means the group consisting of the Company and each present or future parent and subsidiary corporation or other affiliated business entity thereof.

(m)“Equity Award” means an award relating to the Company’s common stock (or an equivalent equity award as assumed, continued or substituted for by an Acquiror), whether a stock option, stock appreciation right, shares of restricted stock, restricted stock units, performance shares, performance units, or other share-based compensation award.
(n)“ERISA” means the Employee Retirement Income Security Act of 1974, as amended.
(o)“Good Reason” means the occurrence of any of the following during a Change in Control Period without the Participant’s written consent:
(1)a material reduction by the Company of the Participant’s Base Salary Rate as in effect immediately prior to such reduction (provided that any reduction by 10% or more in a Participant’s Base Salary Rate shall be treated as material hereunder); or 
(2)the material diminution of the Participant’s authority, position or duties so that the Participant’s duties are no longer consistent with the Participant’s position immediately prior to such change; provided that if the Participant is determined to have a disability, and if the Company offers the Participant the opportunity to remain employed in a different capacity that accommodates the Participant’s disability, with different duties and compensation structure in lieu of termination, such change in responsibilities and compensation shall not constitute Good Reason; or
(3)the relocation of the Participant’s principal work location that increases the Participant’s one-way commuting distance from the Participant’s home to such new work location by thirty (30) miles or more.
Before the Participant may resign for Good Reason, (i) the Participant must provide the Company with a Notice of Termination within ninety (90) days following the initial event that the Participant believes constitutes “Good Reason” specifically identifying the facts and circumstances claimed to constitute the grounds for the Participant’s resignation for Good Reason, and the thirty (30) day Notice Period will commence on the date of delivery of such Notice of Termination.  The Company shall have an opportunity within such Notice Period to cure the Good Reason condition, provided that the Company may waive such cure period by giving written notice to the Participant that it does not intend to cure such condition.  The failure by the Participant to include in the Notice of Termination any fact or circumstance that contributes to a showing of Good Reason will not preclude the Participant from asserting such fact or circumstance in enforcing the Participant’s rights under this Plan.  For the purposes of any determination regarding the existence of Good Reason, any claim by the Participant that Good Reason exists shall be presumed to be correct unless the Company establishes to the Board that Good Reason does not exist, and the Board, acting in good faith, affirms such determination (excluding the Participant if the Participant is a member of the Board).
(p)“Non-CIC Severance Benefit Period” means, for each Participant, the Non-CIC Severance Benefit Period set forth in the Participant’s Participation Agreement, which will apply in connection with a Qualifying Termination that does not occur during a Change in Control Period.
(q)“Non-Qualifying Termination” means any termination of a Participant’s employment with the Company which is not a Qualifying Termination.
(r)“Notice of Termination” means the notice described in Section 4.
(s)“Notice Period” means a period of thirty (30) days commencing on the date of delivery of a Notice of Termination.
(t)“Participant” means an employee of the Company or its subsidiaries who is designated by the Committee to participate in the Plan and who has executed a Participation Agreement.
(u)“Participation Agreement” means an Agreement to Participate in the GenMark Diagnostics, Inc. Executive Severance Plan in the form attached hereto as Exhibit A or in such other form as the Committee may approve from time to time; provided, however, that, after a Participation Agreement has been entered into between a Participant and the Company, it may be modified only by a supplemental written agreement executed by both the Participant and the Company.  The terms of such forms of Participation Agreement need not be identical with respect to each Participant.
(v)“Permanent Disability” means a Participant’s incapacity due to bodily injury or disease which (1) prevents the Participant from engaging in the full-time performance of the Participant’s duties for a period of six (6) 

consecutive months and (2) will, in the opinion of a qualified physician, be permanent and continuous during the remainder of the Participant’s life.
(w)“Pre-Change in Control Period” means that portion of the Change in Control Period occurring prior to the consummation of a Change in Control.
(x)“Qualifying Termination” means, as applicable:
(1)if such termination does not occur during a Change in Control Period, termination by the Company Group of the Participant’s employment for any reason other than Cause; or
(2)if such termination occurs during a Change in Control Period, either (i) termination by the Company Group of the Participant’s employment for any reason other than Cause or (ii) the Participant’s termination of employment with the Company Group for Good Reason, provided that such termination for Good Reason occurs within ninety (90) days following the initial occurrence of the condition constituting Good Reason;
provided, however, that Qualifying Termination shall not include any termination of the Participant’s employment which is (i) for Cause, (ii) a result of the Participant’s death or Permanent Disability, or (iii) a result of the Participant’s voluntary termination of employment other than for Good Reason.
(y)“Release” means a general release of all known and unknown claims against the Company and its affiliates and their stockholders, directors, officers, employees, agents, successors and assigns substantially in the form attached hereto as Exhibit B (“General Release of Claims [Age 40 and over]”) or Exhibit C (“General Release of Claims [Under age 40]”), whichever is applicable, with any modifications thereto determined by legal counsel to the Company to be necessary or advisable to comply with applicable law or to accomplish the intent of Section 10 (Exclusive Remedy) hereof.
(z)“Release Deadline Date” means the sixtieth (60th) day following the Participant’s Termination Date.
(aa)“Section 409A” means Section 409A of the Code.
(bb) “Section 409A Deferred Compensation” means compensation and benefits provided by the Plan that constitute deferred compensation subject to and not exempted from the requirements of Section 409A.
(cc) “Separation from Service” means a separation from service within the meaning of Section 409A.
(dd) “Short-Term Deferral Period” means a period determined in accordance with Treasury Regulation Section 1.409A-1(b)(4) beginning on the Termination Date with respect to a Qualifying Termination of the Participant and ending on the 15th day of the third month following the later of (i) the last day of the calendar year or (ii) the last day of the Company’s taxable year in which, in either case, the Termination Date occurs.
(ee) “Successor” means any successor in interest to substantially all of the business and/or assets of the Company.
(ff) “Target Bonus” means the target amount of Participant’s annual cash incentive bonus for the Company fiscal year in which the Termination Date occurs, determined by assuming achievement of all Company performance goals and individual performance goals at their target levels in accordance with the Company’s annual incentive bonus plan and as established by the Committee.
(gg) “Termination Date” means:
(1)if the Company terminates the Participant’s employment without Cause, the date specified in the Notice of Termination, which shall be the day immediately following completion of the Notice Period commencing on the date on which the Notice of Termination is delivered to the Participant; provided that the Company shall have the option to relieve the Participant of all job duties, positions and responsibilities for all or any part of the Notice Period and provide the Participant with payment at the Participant’s then current Base Salary Rate in lieu of any portion of the Notice Period for which the Participant is so relieved of duty, which amount shall be paid in a lump sum on the Participant’s 

Termination Date, and, in such case, for all purposes of this Plan, the Participant’s Termination Date shall be the date as of which the Participant is relieved of all job duties; and
(2)if the Participant terminates his/her employment with or without Good Reason, the date specified in the Participant’s Notice of Termination, which shall be the day immediately following completion of the Notice Period commencing on the date on which the Notice of Termination is delivered to the Company; provided that the Company may waive all or any part of the Notice Period by giving written notice of such waiver to the Participant and providing the Participant with payment at the Participant’s then current Base Salary Rate in lieu of the portion of the Notice Period waived, which amount shall be paid in a lump sum on the Participant’s Termination Date, and, in such case, for all purposes of this Plan, the Participant’s Termination Date shall be the date as of which the Participant is relieved of all job duties.
Notwithstanding anything contained herein to the contrary, the Termination Date shall not occur until the date on which the Participant incurs a Separation from Service.
2.2    Construction.  Captions and titles contained herein are for convenience only and shall not affect the meaning or interpretation of any provision of the Plan.  Except when otherwise indicated by the context, the singular shall include the plural and the plural shall include the singular.  Use of the term “or” is not intended to be exclusive, unless the context clearly requires otherwise.
3.ELIGIBILITY AND PARTICIPATION
Eligibility to participate in the Plan shall be limited to those employees of the Company and its subsidiaries who are designated by the Committee.  Notwithstanding the foregoing, the individuals eligible to become Participants shall be limited to a select group of management or highly compensated employees within the meaning of Sections 201, 301 and 404 of ERISA.  To become a Participant, an eligible individual must execute a Participation Agreement.
4.NOTICE OF TERMINATION
Any termination of a Participant’s employment by the Company or by the Participant (other than termination on account of the Participant’s death) shall be communicated by written notice of termination (“Notice of Termination”) to the other party hereto in accordance with Section 17.  The Notice of Termination shall specify (a) the facts and circumstances claimed to provide a basis for termination of the Participant’s employment and (b) the applicable Termination Date.
5.NON-QUALIFYING TERMINATION
In the event of a Participant’s Non-Qualifying Termination, the Participant shall be entitled to receive only the Participant’s Accrued Amounts.
6.QUALIFYING TERMINATION
6.1    Not During a Change in Control Period.  In the event of a Participant’s Qualifying Termination that does not occur during a Change in Control Period, the Participant shall be entitled to receive the Participant’s Accrued Amounts.  In addition, provided that the Participant executes a Release that becomes effective and irrevocable on or before the Release Deadline Date, the Participant shall be entitled to receive the following severance payments and benefits:
(a)Base Salary Severance Benefit.  An amount equal to the product of the Participant’s Base Salary Rate and the number of months contained in the Participant’s Non-CIC Severance Benefit Period shall be paid in cash in a single lump sum on the next regular payroll date following the effective date of the Release (but in no event later than the lapsing of the Short-Term Deferral Period).
(b)Health Care Benefit.  Payment by the Company of the premiums required to continue the Participant’s group health care coverage for the same level of health coverage and benefits as in effect for the Participant on the day immediately preceding the Termination Date for the Participant’s Non-CIC Severance Benefit Period following the Termination Date (the “Premium Payment Period”) under the applicable provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), provided that the Participant elects to continue and remains eligible for these benefits under COBRA and does not become eligible for health coverage through another employer during this period.  Notwithstanding the foregoing, if the Company determines, in its reasonable discretion, that either (i) the payment of the premiums would result in a violation of the nondiscrimination rules of Section 105(h)(2) of the Code or any statute or 

regulation of similar effect (including but not limited to the 2010 Patient Protection and Affordable Care Act, as amended by the 2010 Health Care and Education Reconciliation Act) (the “Impermissible Payment”) or (ii) any portion of the Premium Payment Period would exceed the maximum healthcare continuation coverage period available to the Participant under COBRA (the “Excess Payment”), then, in lieu of paying such premiums with respect to the Impermissible Payment or the Excess Payment, the Company, in its sole discretion, may elect to instead pay the Participant on the first day of each month during the Premium Payment Period, a fully taxable cash payment (the “Special Separation Payment”) equal to the Impermissible Payment or the Excess Payment, as applicable, for that month, for the remainder of the Premium Payment Period.  The Special Separation Payment with respect to the Impermissible Payment (but not the Excess Payment) will cease should Executive elect to cease, or become ineligible for, continued health care coverage under COBRA.
6.2    During a Change in Control Period.  In the event of a Participant’s Qualifying Termination that occurs during a Change in Control Period, the Participant shall be entitled to receive the Participant’s Accrued Amounts.  In addition, provided that the Participant executes a Release that becomes effective and irrevocable on or before the Release Deadline Date, the Participant shall be entitled to receive the following severance payments and benefits, reduced by the portion, if any, of such severance payments and benefits previously provided in accordance with Section 6.1 if the Participant’s Qualifying Termination occurred during the Pre-Change in Control Period:
(a)Base Salary Severance Benefit.  An amount equal to the product of the Participant’s Base Salary Rate and the number of months contained in the Participant’s CIC Severance Benefit Period shall be paid in cash in a single lump sum on the next regular payroll date following the later of (i) the effective date of the Release or (ii) the consummation of the Change in Control (but in no event later than the lapsing of the Short-Term Deferral Period).
(b)Bonus Severance Benefit.  An amount equal to the Participant’s Target Bonus shall be paid in cash in a single lump sum on the next regular payroll date following the later of (i) the effective date of the Release or (ii) the consummation of the Change in Control (but in no event later than the lapsing of the Short-Term Deferral Period).
(c)Health Care Benefit.  Payment by the Company of the premiums required to continue the Participant’s group health care coverage for the same level of health coverage and benefits as in effect for the Participant on the day immediately preceding the Termination Date for the Participant’s CIC Severance Benefit Period following the Termination Date under the applicable provisions of COBRA and upon the same terms and subject to the same conditions provided in Section 6.1(b).
7.     INTENTIONALLY OMITTED
8.     CERTAIN TAX MATTERS
8.1    Federal Excise Tax Under Section 4999 of the Code.
(a)Excess Parachute Payments.  If any payments and other benefits provided to a Participant by this Plan or otherwise (collectively, the “Payments”) would, either separately or in the aggregate, constitute “parachute payments” within the meaning of Section 280G of the Code and, but for this Section 8.1, would be subject to the excise tax imposed by Section 4999 of the Code (the “Excise Tax”), then the Payments will be payable to the Participant either in full or in such lesser amounts as would result, after taking into account the applicable federal, state and local income taxes and the Excise Tax, in the Participant’s receipt on an after-tax basis of the greatest amount of Payments, by reducing Payments in the following order: (i) reduction or elimination of cash severance benefits that are subject to Section 409A of the Code; (ii) reduction or elimination of cash severance benefits that are not subject to Section 409A of the Code; (iii) cancellation or reduction of accelerated vesting of Equity Awards that are not stock options or stock appreciation rights; (iv) cancellation or reduction of accelerated vesting of stock options and stock appreciation rights; and (v) reduction or elimination of other Payments.  In the event that acceleration of vesting of Equity Award compensation is to be reduced, such acceleration of vesting shall be cancelled in the reverse order of the date of grant.  If two or more Equity Awards are granted on the same date, the accelerated vesting of each award will be reduced on a pro-rata basis.
(b)Determination by Tax Firm.  The professional firm engaged by the Company for general tax purposes as of the day prior to the date of the event that might reasonably be anticipated to result in Payments that would otherwise be subject to the Excise Tax will perform the foregoing calculations.  If the tax firm so engaged by the Company is serving as accountant or auditor for the Acquiror, the Company will appoint a nationally recognized tax firm to make the determinations required by this Section.  The Company will bear all expenses with respect to the determinations by such firm required to be made by this Section.  The Company and the Participant shall furnish such tax firm such information and documents as the tax firm may reasonably request in order to make its required determination.  The tax firm will provide its 

calculations, together with detailed supporting documentation, to the Company and the Participant as soon as practicable following its engagement.  Any good faith determinations of the tax firm made hereunder will be final, binding and conclusive upon the Company and the Participant.
8.2    Compliance with Section 409A.  The Company intends that this Plan (and all payments and other benefits provided under this Plan) shall be exempt from the requirements of Section 409A to the maximum extent possible, whether pursuant to the short-term deferral exception described in Treasury Regulation Section 1.409A-1(b)(4), the involuntary separation pay plan exception described in Treasury Regulation Section 1.409A-1(b)(9)(iii), or otherwise.  To the extent Section 409A is applicable to such payments, the Company intends that this Plan (and such payments and benefits) shall comply with the requirements of Section 409A.  Notwithstanding any other provision of this Plan to the contrary, this Plan shall be interpreted, operated and administered in a manner consistent with such intentions.  Without limiting the generality of the foregoing, and notwithstanding any other provision of this Plan to the contrary, the provision, time and manner of payment or distribution of all compensation and benefits provided by the Plan that constitute Section 409A Deferred Compensation shall be subject to, limited by and construed in accordance with the requirements of Section 409A, including the following:
(a)Separation from Service.  To the extent required to be exempt from, or to comply with Section 409A, payments and benefits otherwise payable or provided pursuant to the Plan upon a Participant’s Qualifying Termination shall be paid or provided only at the time of a termination of the Participant’s service which constitutes a Separation from Service.
(b)Six-Month Delay Applicable to Specified Employees.  Payments and benefits constituting Section 409A Deferred Compensation to be paid or provided pursuant to the Plan upon the Separation from Service of a Participant who is a “specified employee” within the meaning of Section 409A (determined using the identification methodology selected by the Company from time to time, or if none, the default methodology described in applicable Treasury Regulation) shall be paid or provided only upon the later of (1) the date that is six (6) months and one (1) day after the date of such Separation from Service or, if earlier, the date of death of the Participant (in either case, the “Delayed Payment Date”), or (2) the date or dates on which such Section 409A Deferred Compensation would otherwise be paid or provided in accordance with the Plan.  All such amounts that would, but for this Section, become payable prior to the Delayed Payment Date shall be accumulated and paid on the Delayed Payment Date.
(c)Separate Payments.  Each payment made under this Plan shall be treated as a separate payment, and the right of a Participant to a series of installment payments under this Plan shall be treated as a right to a series of separate payments.
(d)Expense Reimbursements and In-Kind Benefits.  With regard to any provision in this Plan for reimbursement of expenses or in-kind benefits, except for any expense, reimbursement or in-kind benefit provided pursuant to this Plan that does not constitute Section 409A Deferred Compensation, (i) the right to reimbursement or in-kind benefits shall not be subject to liquidation or exchange for another benefit, (ii) the amount of expenses eligible for reimbursement, or in-kind benefits provided, during any taxable year shall not affect the expenses eligible for reimbursement, or in-kind benefits to be provided, in any other taxable year, provided that the foregoing clause (ii) shall not be deemed to be violated with regard to expenses reimbursed under any arrangement covered by Section 105(b) of the Code solely because such expenses are subject to a limit related to the period the arrangement is in effect, and (iii) such payments shall be made on or before the last day of Participant’s taxable year following the taxable year in which the expense occurred.
(e)Intentionally Omitted.  
8.3    Tax Withholding.  The Company shall have the right to withhold from any amount payable under this Plan any Federal, state, local and foreign taxes in order for the Company to satisfy any withholding tax obligation it may have under any applicable law or regulation.
9.     CONFLICT IN BENEFITS; NONCUMULATION OF BENEFITS
9.1    Effect of Plan.  With the exception of any Equity Award agreements, the terms of this Plan, when accepted by a Participant pursuant to an executed Participation Agreement, shall supersede all prior severance pay and benefit arrangements, whether written or oral, and understandings regarding the subject matter of this Plan and, subject to Section 9.2, shall be the exclusive agreement for the determination of any payments and benefits due to the Participant upon the events described in this Plan.

9.2    Noncumulation of Benefits.  Except as expressly provided in a written agreement between a Participant and the Company entered into after the date of such Participant’s Participation Agreement and which expressly disclaims this Section 9.2 and is approved by the Board or the Committee, the total amount of payments and benefits that may be received by the Participant as a result of the events described in (a) the Plan, (b) any agreement between the Participant and the Company, or (c) any other plan, practice or statutory obligation of the Company, shall not exceed the amount of payments and benefits provided by this Plan upon such events, and the aggregate amounts payable under this Plan shall be reduced to the extent of any excess (but not below zero).
10.EXCLUSIVE REMEDY
The payments and benefits provided by this Plan, shall constitute the Participant’s sole and exclusive remedy for any alleged injury or other damages arising out of the cessation of the employment relationship between the Participant and the Company in the event of the Participant’s Qualifying Termination.  The Participant shall be entitled to no other compensation, benefits, or other payments from the Company as a result of the Participant’s Qualifying Termination with respect to which the payments and benefits described in this Plan have been provided to the Participant, except as expressly set forth in this Plan or, subject to the provisions of Section 9.2, in a duly executed employment agreement between Company and the Participant.
11.PROPRIETARY AND CONFIDENTIAL INFORMATION
Each Participant agrees to continue to abide by the terms and conditions of the confidentiality and/or proprietary rights agreement between the Participant and the Company or any other member of the Company Group.
12.NON-SOLICITATION
If the Company performs its obligations to deliver the payments and benefits required by this Plan, then for a period equal to the CIC Severance Benefit Period or Non-CIC Severance Benefit Period applicable to a Participant following the Participant’s Qualifying Termination, the Participant shall not, directly or indirectly, recruit, solicit or invite the solicitation of any employees of the Company or any other member of the Company Group to terminate their employment relationship with the Company Group.
13.NO CONTRACT OF EMPLOYMENT
Neither the establishment of the Plan, nor any amendment thereto, nor the payment or provision of any benefits thereunder shall be construed as giving any person the right to be retained by the Company, a Successor or any other member of the Company Group.  Except as otherwise established in a written employment agreement between the Company and a Participant, the employment relationship between the Participant and the Company is an “at-will” relationship.  Accordingly, either the Participant or the Company may terminate the relationship at any time, with or without cause, and with or without notice except as otherwise provided by Section 4.  In addition, nothing in this Plan shall in any manner obligate any Successor or other member of the Company Group to offer employment to any Participant or to continue the employment of any Participant which it does hire for any specific duration of time.
14.CLAIMS FOR BENEFITS
14.1    ERISA Plan.  This Plan is intended to be (a) an employee welfare benefit plan as defined in Section 3(1) of ERISA and (b) a “top-hat” plan maintained for the benefit of a select group of management or highly compensated employees of the Company Group.
14.2    Application for Benefits.  All applications for payments and/or benefits under the Plan (“Benefits”) shall be submitted to the Company’s Vice President, Human Resources (the “Claims Administrator”), with a copy to the Company’s General Counsel.  Applications for Benefits must be in writing on forms acceptable to the Claims Administrator and must be signed by the Participant or beneficiary.  The Claims Administrator reserves the right to require the Participant or beneficiary to furnish such other proof of the Participant’s expenses, including without limitation, receipts, canceled checks, bills, and invoices as may be required by the Claims Administrator.

14.3    Appeal of Denial of Claim.
(a)If a claimant’s claim for Benefits is denied, the Claims Administrator shall provide notice to the claimant in writing of the denial within ninety (90) days after its submission.  The notice shall be written in a manner calculated to be understood by the claimant and shall include:
(1)The specific reason or reasons for the denial;
(2)References to the specific Plan provisions on which the denial is based;
(3)A description of any additional material or information necessary for the applicant to perfect the claim and an explanation of why such material or information is necessary; and
(4)An explanation of the Plan’s claims review procedures and time limits applicable to such procedures, including a statement of claimant’s right to bring a civil action under ERISA Section 502(a) following an adverse benefit determination.
(b)If special circumstances require an extension of time for processing the initial claim, a written notice of the extension and the reason therefor shall be furnished to the claimant before the end of the initial ninety (90) day period.  In no event shall such extension exceed ninety (90) days.
(c)If a claim for Benefits is denied, the claimant, at the claimant’s sole expense, may appeal the denial to the Committee (the “Appeals Administrator”) within sixty (60) days of the receipt of written notice of the denial.  In pursuing such appeal the claimant or his or her duly authorized representative:
(1)may request in writing that the Appeals Administrator review the denial;
(2)may review pertinent documents; and
(3)may submit issues and comments in writing.
(d)The decision on review shall be made within sixty (60) days of receipt of the request for review, unless special circumstances require an extension of time for processing, in which case a decision shall be rendered as soon as possible, but not later than one hundred twenty (120) days after receipt of the request for review.  If such an extension of time is required, written notice of the extension shall be furnished to the claimant before the end of the original sixty (60) day period.  The decision on review shall be made in writing, shall be written in a manner calculated to be understood by the claimant, and, if the decision on review is a denial of the claim for Benefits, shall include:  
(1)The specific reason or reasons for the denial;
(2)References to the specific Plan provisions on which the denial is based;
(3)A statement that the claimant is entitled to receive, upon request and free of charge, reasonable access to, and copies of, the Plan and all documents, records and other information relevant to his or her claim for benefits; and
(4)A statement of claimant’s right to bring a civil action under ERISA Section 502(a) following an adverse benefit determination.
14.4    Exhaustion of Administrative Remedies.  The exhaustion of these claims procedures is mandatory for resolving every claim and dispute arising under the Plan.  As to such claims and disputes:
(a)No claimant shall be permitted to commence any legal action to recover benefits or to enforce or clarify rights under the Plan under Section 502 or Section 510 of ERISA or under any other provision of law, whether or not statutory, until these claims procedures have been exhausted in their entirety; and
(b)In any such legal action, all explicit and implicit determinations by the Claims Administrator (including, but not limited to, determinations as to whether the claim, or a request for a review of a denied claim, was timely filed) shall be afforded the maximum deference permitted by law.

15.DISPUTE RESOLUTION
In the event of any dispute or claim relating to or arising out of this Plan that is not resolved in accordance with procedure described in Section 14, the Company and the Participant, each by executing a Participation Agreement, agree that all such disputes or claims shall be resolved by means of binding arbitration in San Diego County, California before a sole arbitrator, in accordance with the laws of the State of California for agreements made in that State or as otherwise required by ERISA.  Any arbitration shall be administered by JAMS pursuant to its Comprehensive Arbitration Rules and Procedures.  Judgment on the award may be entered in any court having jurisdiction.  The prevailing party shall be entitled to recover from the losing party its attorneys’ fees and costs incurred in any action brought to enforce any right arising out of this Plan.
16.SUCCESSORS AND ASSIGNS
16.1    Successors of the Company.  The Company shall require any successor or assign (whether direct or indirect, by purchase, merger, consolidation or otherwise) to all or substantially all of the business and/or assets of the Company, expressly, absolutely and unconditionally to assume and agree to perform this Plan in the same manner and to the same extent that the Company would be required to perform it if no such succession or assignment had taken place.
16.2    Heirs and Representatives of Participant.  This Plan shall inure to the benefit of and be enforceable by the Participants’ personal or legal representatives, executors, administrators, successors, heirs, distributees, devises, legatees or other beneficiaries.  If a Participant should die while any amount would still be payable to the Participant hereunder (other than amounts which, by their terms, terminate upon the death of the Participant) if the Participant had continued to live, then all such amounts, unless otherwise provided herein, shall be paid in accordance with the terms of this Plan to the executors, personal representatives or administrators of the Participant’s estate.
17.NOTICES
For purposes of this Plan, notices and all other communications provided for herein shall be in writing and shall be deemed to have been duly given when personally delivered or when mailed by United States certified mail, return receipt requested, or by overnight courier, postage prepaid, as follows:
(a)if to the Company:
GenMark Diagnostics, Inc.
5964 La Place Court
Carlsbad, California 92008
Attention: General Counsel
(b)    if to the Participant, at the home address which the Participant most recently communicated to the Company in writing.
Either party may provide the other with notices of change of address, which shall be effective upon receipt.
18.TERMINATION AND AMENDMENT OF PLAN
Unless extended by the Board or the Committee, the Plan and all Participation Agreements shall expire on the third (3rd) anniversary of the Effective Date.  Except as provided by the preceding sentence, the Plan and/or any Participation Agreement executed by a Participant may not be terminated with respect to such Participant without the written consent of the Participant and the approval of the Board or the Committee.  The Plan and/or any Participation Agreement executed by a Participant may be modified, amended or superseded with respect to such Participant only by a supplemental written agreement between the Participant and the Company approved by the Board or the Committee.  Notwithstanding any other provision of the Plan to the contrary, the Board for the Committee may, in its sole and absolute discretion and without the consent of any Participant, amend the Plan or any Participation Agreement, to take effect retroactively or otherwise, as it deems necessary or advisable for the purpose of conforming the Plan or such Participation Agreement to any present or future law relating to plans of this or similar nature (including, but not limited to, Section 409A of the Code), and to the administrative regulations and rulings promulgated thereunder.

19.MISCELLANEOUS PROVISIONS
19.1    Administration.  The Plan shall be administered by the Committee.  The Committee shall have the exclusive discretion and authority to establish rules, forms and procedures for the administration of the Plan, to construe and interpret the Plan, and to decide all questions of fact, interpretation, definition, computation or administration arising in connection with the Plan, including, but not limited to, eligibility to participate in the Plan and the amount of benefits paid under the Plan.  The rules, interpretations and other actions of the Committee shall be binding and conclusive on all persons.  All expenses incurred in connection with the administration of the Plan, including the claims procedures described in Section 14, shall be paid by the Company.
19.2    Unfunded Obligation.  Any amounts payable to Participants pursuant to the Plan are unfunded obligations.  The Company shall not be required to segregate any monies from its general funds, or to create any trusts, or establish any special accounts with respect to such obligations.  The Company shall retain at all times beneficial ownership of any investments, including trust investments, which the Company may make to fulfill its payment obligations hereunder.  Any investments or the creation or maintenance of any trust or any Participant account shall not create or constitute a trust or fiduciary relationship between the Board or the Company and a Participant, or otherwise create any vested or beneficial interest in any Participant or the Participant’s creditors in any assets of the Company.
19.3    No Duty to Mitigate; Obligations of Company.  A Participant shall not be required to mitigate the amount of any payment or benefit contemplated by this Plan by seeking employment with a new employer or otherwise, nor shall any such payment or benefit (except for the benefits described in Section 6.1(b) or Section 6.2(c)) be reduced by any compensation or benefits that the Participant may receive from employment by another employer.  Except as otherwise provided by this Plan, the obligations of the Company to make payments to the Participant and to make the arrangements provided for herein are absolute and unconditional and may not be reduced by any circumstances, including without limitation any set-off, counterclaim, recoupment, defense or other right which the Company may have against the Participant or any third party at any time.
19.4    Recoupment.  Without the consent of any Participant and notwithstanding any other provision of this Plan or any other agreement between the Participant and the Company to the contrary, any incentive-based compensation, or any other compensation, paid to the Participant pursuant to this Plan or any other agreement or arrangement with the Company which is subject to recovery under any law, government regulation or stock exchange listing requirement, will be subject to such deductions and recoupment as may be required to be made pursuant to such law, government regulation or stock exchange listing requirement (or any policy adopted by the Company pursuant to any such law, government regulation or stock exchange listing requirement).  This Section 19.4 shall survive the termination of this Plan for a period equal to the greater of (a) three (3) years and (b) such longer period required by the applicable law, government regulation, order or stock exchange listing requirement.
19.5    No Representations.  By executing a Participation Agreement, the Participant acknowledges that in becoming a Participant in the Plan, the Participant is not relying and has not relied on any promise, representation or statement made by or on behalf of the Company which is not set forth in this Plan.
19.6    Waiver.  No waiver by the Participant or the Company of any breach of, or of any lack of compliance with, any condition or provision of this Plan by the other party shall be considered a waiver of any other condition or provision or of the same condition or provision at another time.
19.7    Choice of Law.  The validity, interpretation, construction and performance of this Plan shall be governed by the substantive laws of the State of California, without regard to its conflict of law provisions.
19.8    Validity.  The invalidity or unenforceability of any provision of this Plan shall not affect the validity or enforceability of any other provision of this Plan, which shall remain in full force and effect.
19.9    Benefits Not Assignable.  Except as otherwise provided herein or by law, no right or interest of any Participant under the Plan shall be assignable or transferable, in whole or in part, either directly or by operation of law or otherwise, including, without limitation, by execution, levy, garnishment, attachment, pledge or in any other manner, and no attempted transfer or assignment thereof shall be effective.  No right or interest of any Participant under the Plan shall be liable for, or subject to, any obligation or liability of such Participant.
19.10    Consultation with Legal and Financial Advisors.  By executing a Participation Agreement, the Participant acknowledges that this Plan confers significant legal rights, and may also involve the waiver of rights under other 

agreements; that the Company has encouraged the Participant to consult with the Participant’s personal legal and financial advisors; and that the Participant has had adequate time to consult with the Participant’s advisors before executing the Participation Agreement.
19.11    Further Assurances.  From time to time, at the Company’s request and without further consideration, the Participant shall execute and deliver such additional documents and take all such further action as reasonably requested by the Company to be necessary or desirable to make effective, in the most expeditious manner possible, the terms of the Plan, the Participant’s Participation Agreement and the Release, and to provide adequate assurance of the Participant’s due performance thereunder.
20.Agreement
By executing a Participation Agreement, the Participant acknowledges that the Participant has received a copy of this Plan and has read, understands and is familiar with the terms and provisions of this Plan.  This Plan shall constitute an agreement between the Company and the Participant executing a Participation Agreement.
IN WITNESS WHEREOF, the undersigned Secretary of the Company certifies that the foregoing sets forth the Plan as duly adopted by the Committee on July 31, 2019.

/s/ Eric Stier    
Eric Stier, Secretary

    

EXHIBIT A

FORM OF

AGREEMENT TO PARTICIPATE IN THE

GENMARK DIAGNOSTICS, INC.

EXECUTIVE SEVERANCE PLAN

AGREEMENT TO PARTICIPATE IN THE
GENMARK DIAGNOSTICS, INC.
EXECUTIVE SEVERANCE PLAN
In consideration of the benefits provided by the GenMark Diagnostics, Inc. Executive Severance Plan (the “Plan”), the undersigned employee of GenMark Diagnostics, Inc. (the “Company”) and the Company agree that, as of the date written below, the undersigned shall become a Participant in the Plan and shall be fully bound by and subject to all of its provisions.  All references to a “Participant” in the Plan shall be deemed to refer to the undersigned.

Definitions.  For the purposes of the Participant’s participation in the Plan, certain capitalized terms shall have the following meanings:

		
	1.
	“CIC Severance Benefit Period” means a period of [twelve (12)] [nine (9)] [six (6)] months.

		
	2.
	“Non-CIC Severance Benefit Period” means a period of six (6) months.

The undersigned employee acknowledges that the Plan confers significant legal rights and may also constitute a waiver of rights under other agreements with the Company; that the Company has encouraged the undersigned to consult with the undersigned’s personal legal and financial advisors; and that the undersigned has had adequate time to consult with the undersigned’s advisors before executing this agreement.

The undersigned employee acknowledges that he or she has received a copy of the Plan and has read, understands and is familiar with the terms and provisions of the Plan.  The undersigned employee further acknowledges that (1) by accepting the arbitration provision set forth in Section 15 of the Plan, the undersigned is waiving any right to a jury trial in the event of any dispute covered by such provision and (2) except as otherwise established in a written employment agreement between the Company and the undersigned, the employment relationship between the undersigned and the Company is an “at-will” relationship.

Executed as of July 31, 2019.

	
			
	PARTICIPANT
	 
	GENMARK DIAGNOSTICS, INC.

	 
	 
	 

	________________________________
	 
	By:______________________________

	Signature
	 
	 

	 
	 
	 

	________________________________
	 
	Title:____________________________

	Name Printed
	 
	 

	 
	 
	 

	________________________________
	 
	 

	Address__________________________
	 
	 

	 
	 
	 

EXHIBIT B

FORM OF

GENERAL RELEASE OF CLAIMS
[Age 40 and over]

GENERAL RELEASE OF CLAIMS
[Age 40 and over]

This Agreement is by and between [Employee Name] (“Employee”) and [GenMark Diagnostics, Inc. or Successor that agrees to assume the Executive Severance Plan] (the “Company”).  This Agreement will become effective on the eighth (8th) day after it is signed by Employee (the “Effective Date”), provided that the Company has signed this Agreement and Employee has not revoked this Agreement (by written notice to [Company Contact Name] at the Company) prior to that date.

RECITALS
A.    Employee was employed by the Company as of ___________, ____.

B.    Employee and the Company entered into an Agreement to Participate in the GenMark Diagnostics, Inc. Executive Severance Plan (such agreement and plan being referred to herein as the “Plan”) effective as of __________, ____ wherein Employee is entitled to receive certain benefits in the event of an Qualifying Termination (as defined by the Plan), provided Employee signs and does not revoke a Release (as defined by the Plan).

C.    Employee’s employment has been terminated as a result of an Qualifying Termination (as defined by the Plan).  Employee’s last day of work and termination are effective as of _______________, ____.  Employee desires to receive the payments and benefits provided by the Plan by executing this Release.

NOW, THEREFORE, the parties agree as follows:

1.    Commencing on the Effective Date, the Company shall provide Employee with the applicable payments and benefits set forth in the Plan in accordance with the terms of the Plan.  Employee acknowledges that the payments and benefits made pursuant to this paragraph are made in full satisfaction of the Company’s obligations under the Plan.  Employee further acknowledges that Employee has been paid all wages and accrued, unused vacation that Employee earned during his or her employment with the Company.

2.    Employee and Employee’s successors release the Company, its respective subsidiaries, stockholders, investors, directors, officers, employees, agents, attorneys, insurers, legal successors and assigns of and from any and all claims, actions and causes of action, whether now known or unknown, which Employee now has, or at any other time had, or shall or may have against those released parties based upon or arising out of any matter, cause, fact, thing, act or omission whatsoever directly related to Employee’s employment by the Company or the termination of such employment and occurring or existing at any time up to and including the Effective Date, including, but not limited to, any claims of breach of written contract, wrongful termination, retaliation, fraud, defamation, infliction of emotional distress, or national origin, race, age, sex, sexual orientation, disability or other discrimination or harassment under the Civil Rights Act of 1964, the Age Discrimination In Employment Act of 1967, the Americans with Disabilities Act, the Fair Employment and Housing Act or any other applicable law.  Notwithstanding the foregoing, this release shall not apply to any right of the Employee to receive the applicable payments and benefits set forth in the Plan in accordance with the terms of the Plan.

3.    Employee acknowledges that he or she has read Section 1542 of the Civil Code of the State of California, which states in full:

A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.
Employee waives any rights that Employee has or may have under Section 1542 and comparable or similar provisions of the laws of other states in the United States to the full extent that he or she may lawfully waive such rights pertaining to this general release of claims, and affirms that Employee is releasing all known and unknown claims that he or she has or may have against the parties listed above.
4.    Employee and the Company acknowledge and agree that they shall continue to be bound by and comply with the terms and obligations under the following agreements: (i) any proprietary rights or confidentiality agreements between the Company and Employee, (ii) the Plan, and (iii) any Equity Award agreements between the Company and Employee.

5.    This Agreement shall be binding upon, and shall inure to the benefit of, the parties and their respective successors, assigns, heirs and personal representatives.

6.    The parties agree that any and all disputes that both (i) arise out of the Plan, the interpretation, validity or enforceability of the Plan or the alleged breach thereof and (ii) relate to the enforceability of this Agreement or the interpretation of the terms of this Agreement shall be subject to the provisions of Section 14 and Section 15 of the Plan.

7.    The parties agree that any and all disputes that (i) do not arise out of the Plan, the interpretation, validity or enforceability of the Plan or the alleged breach thereof and (ii) relate to the enforceability of this Agreement, the interpretation of the terms of this Agreement or any of the matters herein released or herein described shall be resolved by means of a court trial conducted by the superior or district court in San Diego County, California.  The parties hereby irrevocably waive their respective rights to have any such disputes tried to a jury, and the parties hereby agree that such courts will have personal and subject matter jurisdiction over all such disputes.  Notwithstanding the foregoing, in the event of any such dispute, the parties may agree to mediate or arbitrate the dispute on such terms and conditions as may be agreed in writing by the parties.  The prevailing party shall be entitled to recover from the losing party its attorneys’ fees and costs incurred in any action brought to resolve any such dispute.

8.    This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations and agreements, whether written or oral, with the exception of any agreements described in paragraph 4 of this Agreement.  This Agreement may not be modified or amended except by a document signed by an authorized officer of the Company and Employee.  If any provision of this Agreement is deemed invalid, illegal or unenforceable, such provision shall be modified so as to make it valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions of this Agreement shall not in any way be affected.

EMPLOYEE UNDERSTANDS THAT EMPLOYEE SHOULD CONSULT WITH AN ATTORNEY PRIOR TO SIGNING THIS AGREEMENT AND THAT EMPLOYEE IS GIVING UP ANY LEGAL CLAIMS EMPLOYEE HAS AGAINST THE PARTIES RELEASED ABOVE BY SIGNING THIS AGREEMENT.  EMPLOYEE FURTHER UNDERSTANDS THAT EMPLOYEE MAY HAVE UP TO [21] [45] DAYS TO CONSIDER THIS AGREEMENT, THAT EMPLOYEE MAY REVOKE IT AT ANY TIME DURING THE 7 DAYS AFTER EMPLOYEE SIGNS IT, AND THAT IT SHALL NOT BECOME EFFECTIVE UNTIL THAT 7-DAY PERIOD HAS PASSED.  EMPLOYEE ACKNOWLEDGES THAT EMPLOYEE IS SIGNING THIS AGREEMENT KNOWINGLY, WILLINGLY AND VOLUNTARILY IN EXCHANGE FOR THE COMPENSATION AND BENEFITS DESCRIBED IN PARAGRAPH 1.

	
			
	Dated:___________________________________________
	 
	________________________________________________

	 
	 
	[Employee Name]

	Dated:___________________________________________
	 
	

[Company]

By:_____________________________________________

 
EXHIBIT C

FORM OF

GENERAL RELEASE OF CLAIMS
[Under age 40]

GENERAL RELEASE OF CLAIMS
[Under age 40]

This Agreement is by and between [Employee Name] (“Employee”) and [GenMark Diagnostics, Inc. or Successor that agrees to assume the Executive Severance Plan] (the “Company”).  This Agreement is effective on the day it is signed by Employee (the “Effective Date”).

RECITALS
A.    Employee was employed by the Company as of ____________, ____.

B.    Employee and the Company entered into an Agreement to Participate in the GenMark Diagnostics, Inc. Executive Severance Plan (such agreement and plan being referred to herein as the “Plan”) effective as of ___________, ____ wherein Employee is entitled to receive certain benefits in the event of an Qualifying Termination (as defined by the Plan), provided Employee signs a Release (as defined by the Plan).

C.    Employee’s employment has been terminated as a result of an Qualifying Termination (as defined by the Plan).  Employee’s last day of work and termination are effective as of ______________, ____ (the “Termination Date”).  Employee desires to receive the payments and benefits provided by the Plan by executing this Release.

NOW, THEREFORE, the parties agree as follows:

1.    Commencing on the Effective Date, the Company shall provide Employee with the applicable payments and benefits set forth in the Plan in accordance with the terms of the Plan.  Employee acknowledges that the payments and benefits made pursuant to this paragraph are made in full satisfaction of the Company’s obligations under the Plan.  Employee further acknowledges that Employee has been paid all wages and accrued, unused vacation that Employee earned during his or her employment with the Company.

2.    Employee and Employee’s successors release the Company, its respective subsidiaries, stockholders, investors, directors, officers, employees, agents, attorneys, insurers, legal successors and assigns of and from any and all claims, actions and causes of action, whether now known or unknown, which Employee now has, or at any other time had, or shall or may have against those released parties based upon or arising out of any matter, cause, fact, thing, act or omission whatsoever directly related to Employee’s employment by the Company or the termination of such employment and occurring or existing at any time up to and including the Termination Date, including, but not limited to, any claims of breach of written contract, wrongful termination, retaliation, fraud, defamation, infliction of emotional distress, or national origin, race, age, sex, sexual orientation, disability or other discrimination or harassment under the Civil Rights Act of 1964, the Age Discrimination In Employment Act of 1967, the Americans with Disabilities Act, the Fair Employment and Housing Act or any other applicable law.  Notwithstanding the foregoing, this release shall not apply to any right of the Employee to receive the applicable payments and benefits set forth in the Plan in accordance with the terms of the Plan.

3.    Employee acknowledges that he or she has read Section 1542 of the Civil Code of the State of California, which states in full:

A general release does not extend to claims which the creditor does not know or suspect to exist in his or her favor at the time of executing the release, which if known by him or her must have materially affected his or her settlement with the debtor.
Employee waives any rights that Employee has or may have under Section 1542 and comparable or similar provisions of the laws of other states in the United States to the full extent that he or she may lawfully waive such rights pertaining to this general release of claims, and affirms that Employee is releasing all known and unknown claims that he or she has or may have against the parties listed above.
4.    Employee and the Company acknowledge and agree that they shall continue to be bound by and comply with the terms and his obligations under the following agreements: (i) any proprietary rights or confidentiality agreements between the Company and Employee, (ii) the Plan, and (iii) any Equity Award agreements between the Company and Employee.

5.    This Agreement shall be binding upon, and shall inure to the benefit of, the parties and their respective successors, assigns, heirs and personal representatives.

6.    The parties agree that any and all disputes that both (i) arise out of the Plan, the interpretation, validity or enforceability of the Plan or the alleged breach thereof and (ii) relate to the enforceability of this Agreement or the interpretation of the terms of this Agreement shall be subject to Section 14 and Section 15 of the Plan.

7.    The parties agree that any and all disputes that (i) do not arise out of the Plan, the interpretation, validity or enforceability of the Plan or the alleged breach thereof and (ii) relate to the enforceability of this Agreement, the interpretation of the terms of this Agreement or any of the matters herein released or herein described shall be resolved by means of a court trial conducted by the superior or district court in San Diego County, California.  The parties hereby irrevocably waive their respective rights to have any such disputes tried to a jury, and the parties hereby agree that such courts will have personal and subject matter jurisdiction over all such disputes.  Notwithstanding the foregoing, in the event of any such dispute, the parties may agree to mediate or arbitrate the dispute on such terms and conditions as may be agreed in writing by the parties.  The prevailing party shall be entitled to recover from the losing party its attorneys’ fees and costs incurred in any action brought to resolve any such dispute.

8.    This Agreement constitutes the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior negotiations and agreements, whether written or oral, with the exception of any agreements described in paragraph 4 of this Agreement.  This Agreement may not be modified or amended except by a document signed by an authorized officer of the Company and Employee.  If any provision of this Agreement is deemed invalid, illegal or unenforceable, such provision shall be modified so as to make it valid, legal and enforceable, and the validity, legality and enforceability of the remaining provisions of this Agreement shall not in any way be affected.

EMPLOYEE UNDERSTANDS THAT EMPLOYEE SHOULD CONSULT WITH AN ATTORNEY PRIOR TO SIGNING THIS AGREEMENT AND THAT EMPLOYEE IS GIVING UP ANY LEGAL CLAIMS EMPLOYEE HAS AGAINST THE PARTIES RELEASED ABOVE BY SIGNING THIS AGREEMENT.  EMPLOYEE ACKNOWLEDGES THAT EMPLOYEE IS SIGNING THIS AGREEMENT KNOWINGLY, WILLINGLY AND VOLUNTARILY IN EXCHANGE FOR THE COMPENSATION AND BENEFITS DESCRIBED IN PARAGRAPH 1.

	
			
	Dated:___________________________________________
	 
	________________________________________________

	 
	 
	[Employee Name]

	Dated:___________________________________________
	 
	

[Company]

By:_____________________________________________

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00301-of-00352.parquet"}]]